Please assess the completion status of the following clinical trial:

Trial Title: Botulinum Toxin Type A for the Treatment of Male Chronic Pelvic Pain Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* CPPS NIH III (symptoms over 3 months during the last 6 months, 4 glass-test)~* Pain Score ≥ 4~Exclusion Criteria:~* During the last month: intake of antibiotics, alpha receptor blockers, anticholinergics; intake of analgesics containing opioids (longer than 4 days); participating in a different clinical trial~* During the last 3 months:documented urinary infection, epididymitis, positive urinary culture; status post biopsy of the prostate gland; STD: Gonorrhea, Chlamydia, Mycoplasm, Trichomonads~* During the last 6 months: Finasteride or any other 5α-reductase inhibitor~* During the last 12 months: status post any surgery on the prostate gland; genital herpes; not adjustable hypertension, angina pectoris, heart failure (NYHA III-IV), Status post myocardial infarction, coronary bypass surgery or coronary dilatation~* During the last 24 months: cerebral insult, TIA; active disease of the liver~* Other urological diseases like prostate cancer, bladder cancer, status post radiation of the small pelvis, chemotherapy (intravesical or systemic)~* Urinary catheter~* Residual urine \> 200ml~* Serum creatinine \> 200µmol/l~* Status post injection of BTX A, hypersensitivity concerning any substances of content of BTX, myasthenia gravis~* Any kind of cancer~* Active inflammation (except the prostate gland)~* Neurological or psychological disease making signing of a consent form or behaving according to a study protocol impossible~* Abuse of drugs or alcohol during last 5 years~* Any disease that may influence the results according to the opinion of the medical doctor

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Botulinum Toxin Type A 200 U in 4ml NaCl 0.9%
- 2 (Type: PLACEBO_COMPARATOR): 4ml NaCl 0.9%

Based on this trial design, predict the completion outcome and termination type (if applicable).